The Biosensor Platform

The Biosensor is a Platform for Multiple Diagnostic Tests

World-first Organic Thin Film Transistor (OTFT) technology.

The Biosensor Platform is a small, printable organic strip designed to put the power of accurate, timely diagnosis in the hands of patients and their primary health practitioners.

By altering the detection element (region A) depending on the specific analyte of interest, we can produce a complete portfolio of non-invasive, real-time, saliva-based diagnostic tests.

Because both the core OTFT sensing element and the mechanism of action remain the same, tests developed from the Biosensor Platform have the potential to be printed at scale and low cost.

Behind the technology

Meet the team behind the biosensor technology at the Centre for Organic Electronics at the University of Newcastle.

Play Video about The Saliva Glucose Biosensor Platform

Our Journey

The Story of the Biosensor

1997

Research Begins

Professor Paul Dastoor and University of Newcastle team began research into conducting polymers.

2013

IP Filed

IP for Organic Thin-Film Transistor (OTFT) technology filed.

2014

Publication

“Detection of saliva-range glucose concentrations using organic thin-film transistors”, Applied Physics Letters, 105, 043303 (2014).

2016

IP Acquired

The iQ Group Global acquires OTFT technology for diabetes management and accelerates development into medical device.

2017

US Patent Granted

Patent: US 9,766,199B2
Original IP protected to 2033, with more patents to be filed. Ongoing development by original scientific team.

2018

GBS Inc.

Leadership team established for GBS Inc.

Biosensor Platform Pipeline Extended
GBS Inc. announces extension of research and development of biosensor for additional indications including cancer, allergen and hormone biomarkers.

China Patent Granted
Patent: CN201380022888.2

2019

Publication

GenomeWeb acknowledges the Saliva Glucose Biosensor as leading the race to the “holy grail” of life sciences.

2020

FDA Regulatory Submission

commences for De Novo classification of the Saliva Glucose Biosensor.

COVID-19 Antibody Program
Collaboration with Wyss Institute for Biologically Inspired Engineering at Harvard University commences for COVID-19 antibody program.

GBS Inc. IPO (NASDAQ)

2021

Research

GBS Inc. enters sponsored research agreement with Johns Hopkins Bloomberg School of Public Health to accelerate development of saliva-based diagnostic tests.

Government Grant

GBS awarded $4.7 Million Australian Federal Government Science Grant to manufacture Biosensor technology.

2022

Clinical Trials

GBS Inc. announces institutional review board approval to initiate clinical trial at Sutter Health Mills-Peninsula Medical Center.

Manufacturing

GBS Inc. initiates manufacturing on the University of Newcastle Australia campus.

About the Centre for Organic Electronics

The University of Newcastle

The biosensor was invented at the Priority Research Centre for Organic Electronics at The University of Newcastle, Australia.

The Centre for Organic Electronics is the first of its kind in Australia. It is an exciting new initiative focusing on the development of new electronic devices at the intersection between semiconductors and plastics.

The Centre focuses on the scientific challenges in the development of organic electronics, with massive potential for the next generation of environmentally friendly energy sources, photonics and biosensors.

Future Tests

Development has commenced on an complete portfolio of tests including cancer markers, hormones and allergens.